GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis’ Zolgensma. More: Novartis, Sarepta tipped to drive genomic therapy sales toward
read moreSix years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. The FDA has approved a third indication for Welireg, signing off on the hypoxia-inducible factor-2 alpha inhibitor
read moreThe FDA granted an accelerated approval to AbbVie’s c-Met-directed ADC Emrelis as a new treatment option for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer who’ve previously received systemic therapy. The green light equips AbbVie with a
read moreAdd Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald Trump continues to ramp up pressure on the biopharma industry. On Wednesday, Sanofi said it will invest at least $20
read more
Trial progresses towards topline data expected later in the year More: Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease Source: News
read more
FDA recognises KER-0193 as a potential therapy for rare paediatric disease More: Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals